These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 26541323

  • 1. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
    Fabis-Pedrini MJ, Xu W, Burton J, Carroll WM, Kermode AG.
    J Clin Neurosci; 2016 Mar; 25():145-7. PubMed ID: 26541323
    [Abstract] [Full Text] [Related]

  • 2. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [Abstract] [Full Text] [Related]

  • 3. Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature.
    Zhang Y, Wright C, Flores A.
    J Med Case Rep; 2018 Jul 01; 12(1):187. PubMed ID: 29960601
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
    Yap SM, McGuigan C.
    Mult Scler; 2017 May 01; 23(6):765-767. PubMed ID: 28287039
    [No Abstract] [Full Text] [Related]

  • 7. Quantitative electroencephalography supports diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
    Classen G, Classen C, Bernasconi C, Brandt C, Gold R, Chan A, Hoepner R.
    J Neurovirol; 2019 Feb 01; 25(1):133-136. PubMed ID: 30414049
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
    Dong-Si T, Gheuens S, Gangadharan A, Wenten M, Philip J, McIninch J, Datta S, Richert N, Bozic C, Bloomgren G, Richman S, Weber T, Clifford DB.
    J Neurovirol; 2015 Dec 01; 21(6):637-44. PubMed ID: 25771865
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
    Rath L, Vijiaratnam N, Skibina O.
    Intern Med J; 2017 Feb 01; 47(2):194-199. PubMed ID: 27862809
    [Abstract] [Full Text] [Related]

  • 12. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
    Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag BM, Polman CH, Killestein J.
    Mult Scler; 2015 Apr 01; 21(4):481-4. PubMed ID: 25078275
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Successful pregnancy after natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis.
    Pitarokoili K, Hellwig K, Lukas C, Gold R.
    Mult Scler; 2017 Mar 01; 23(3):483-486. PubMed ID: 28260421
    [Abstract] [Full Text] [Related]

  • 15. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Peaureaux D, Pignolet B, Biotti D, Bucciarelli F, Gaina J, Bucur C, Clanet M, Martin-Blondel G, Brassat D.
    Mult Scler; 2015 Apr 01; 21(5):671-2. PubMed ID: 25305251
    [No Abstract] [Full Text] [Related]

  • 16. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP.
    Clin Ther; 2016 Mar 01; 38(3):670-5. PubMed ID: 26856928
    [Abstract] [Full Text] [Related]

  • 17. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.
    Hervás JV, Presas-Rodríguez S, Crespo-Cuevas AM, Canento T, Lozano-Sánchez M, Massuet-Vilamajó A, Ramo-Tello C.
    Neurodegener Dis Manag; 2015 Oct 01; 5(5):399-402. PubMed ID: 26517599
    [Abstract] [Full Text] [Related]

  • 18. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 19. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, Roosendaal SD, Sanchez E, Liu Y, Martins Jarnalo CO, Richert ND, Uitdehaag BM, Barkhof F, Killestein J.
    Mult Scler; 2016 Aug 17; 22(9):1174-83. PubMed ID: 26564995
    [Abstract] [Full Text] [Related]

  • 20. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, de Vos M, Warnke C, Uitdehaag BMJ, Barkhof F, Killestein J, Wattjes MP.
    JAMA Neurol; 2018 Jul 01; 75(7):827-833. PubMed ID: 29532061
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.